Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symptom relief is main take-away from either OTC or Rx DTC ads, advertiser notes.

This article was originally published in The Tan Sheet

Executive Summary

SYMPTOM RELIEF IS MAJOR TAKE-AWAY FROM EITHER OTC OR DTC Rx ADS, TRL Consumer Advertising President Shane Kennedy said during a presentation at the PharMillenium pharmaceutical congress in Stuart, Fla. Jan. 28-30. "What we've found through the course of ad testing and market research is that consumers recognize the difference in Rx and OTC brands, but when they are watching advertising and hearing communications, all they are interested in is symptom relief," Kennedy said. Consumers "are not really worried where [the medication] comes from, whether it's OTC or Rx, so from the communication standpoint, they are listening to all the messages when it comes to symptom relief."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel